Javier Bolaños-Meade1, Robert A Brodsky. 1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Abstract
PURPOSE OF REVIEW: Sickle cell disease (SCD) is a common health problem in the United States; yet, the only curative therapy, a bone marrow transplant (BMT), is seldom applied. The objective of this report is to review the most recent clinical trials involving blood and BMT for SCD and to discuss novel approaches to overcome the many barriers to successful use of BMT for SCD. RECENT FINDINGS: In select patients, disease-free and overall survival is greater than 80% following matched sibling BMT for SCD. Unfortunately, most patients with SCD do not have a suitable human lymphocyte antigen-matched sibling donor. In an attempt to expand the donor pool, several groups are beginning to explore the use of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood. SUMMARY: The curative potential of BMT in SCD is irrefutable, with outstanding results in children following a myeloablative conditioning regimen and a matched sibling donor transplant. Well tolerated and effective application of alternative sources of stem cells for BMT in SCD could greatly increase the cure rate for this devastating disease.
PURPOSE OF REVIEW: Sickle cell disease (SCD) is a common health problem in the United States; yet, the only curative therapy, a bone marrow transplant (BMT), is seldom applied. The objective of this report is to review the most recent clinical trials involving blood and BMT for SCD and to discuss novel approaches to overcome the many barriers to successful use of BMT for SCD. RECENT FINDINGS: In select patients, disease-free and overall survival is greater than 80% following matched sibling BMT for SCD. Unfortunately, most patients with SCD do not have a suitable human lymphocyte antigen-matched sibling donor. In an attempt to expand the donor pool, several groups are beginning to explore the use of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood. SUMMARY: The curative potential of BMT in SCD is irrefutable, with outstanding results in children following a myeloablative conditioning regimen and a matched sibling donor transplant. Well tolerated and effective application of alternative sources of stem cells for BMT in SCD could greatly increase the cure rate for this devastating disease.
Authors: B Eggleston; M Patience; S Edwards; T Adamkiewicz; G R Buchanan; S C Davies; R Dickerhoff; S Donfield; S A Feig; R H Giller; A Haight; J Horan; L L Hsu; N Kamani; P Lane; J E Levine; D Margolis; T B Moore; K Ohene-Frempong; R Redding-Lallinger; I A G Roberts; Z R Rogers; J E Sanders; J P Scott; B Sleight; A A Thompson; K M Sullivan; M C Walters Journal: Br J Haematol Date: 2007-02 Impact factor: 6.998
Authors: Julie A Panepinto; Mark C Walters; Jeanette Carreras; Judith Marsh; Christopher N Bredeson; Robert Peter Gale; Gregory A Hale; John Horan; Jill M Hows; John P Klein; Ricardo Pasquini; Irene Roberts; Keith Sullivan; Mary Eapen; Alina Ferster Journal: Br J Haematol Date: 2007-04-24 Impact factor: 6.998
Authors: Robert Iannone; James F Casella; Ephraim J Fuchs; Allen R Chen; Richard J Jones; Ann Woolfrey; Michael Amylon; Keith M Sullivan; Rainer F Storb; Mark C Walters Journal: Biol Blood Marrow Transplant Date: 2003-08 Impact factor: 5.742
Authors: Tom V Adamkiewicz; Paul Szabolcs; Ann Haight; K Scott Baker; Susan Staba; Amos Kedar; K Y Chiang; Lakshmanan Krishnamurti; Michael W Boyer; Joan Kurtzberg; John E Wagner; John R Wingard; Andrew M Yeager Journal: Pediatr Transplant Date: 2007-09
Authors: K P Daly; S D Colan; E D Blume; R Margossian; K Gauvreau; C Duncan; L E Lehmann; M H Chen Journal: Bone Marrow Transplant Date: 2011-01-31 Impact factor: 5.483
Authors: Lisa V E Oostenbrink; Emma S Pool; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Carly Vervat; Astrid G S van Halteren; Robbert G M Bredius; Frans J W Smiers; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester; Alexander B Mohseny Journal: Bone Marrow Transplant Date: 2021-05-03 Impact factor: 5.483
Authors: Joseph Long; Megan D Hoban; Aaron R Cooper; Michael L Kaufman; Caroline Y Kuo; Beatriz Campo-Fernandez; Dianne Lumaquin; Roger P Hollis; Xiaoyan Wang; Donald B Kohn; Zulema Romero Journal: Mol Ther Date: 2017-11-09 Impact factor: 11.454
Authors: Nancy A Omondi; Stacy E Stickney Ferguson; Navneet S Majhail; Ellen M Denzen; George R Buchanan; Ann E Haight; Richard J Labotka; J Douglas Rizzo; Elizabeth A Murphy Journal: J Pediatr Hematol Oncol Date: 2013-05 Impact factor: 1.289
Authors: Zulema Romero; Fabrizia Urbinati; Sabine Geiger; Aaron R Cooper; Jennifer Wherley; Michael L Kaufman; Roger P Hollis; Rafael Ruiz de Assin; Shantha Senadheera; Arineh Sahagian; Xiangyang Jin; Alyse Gellis; Xiaoyan Wang; David Gjertson; Satiro Deoliveira; Pamela Kempert; Sally Shupien; Hisham Abdel-Azim; Mark C Walters; Herbert J Meiselman; Rosalinda B Wenby; Theresa Gruber; Victor Marder; Thomas D Coates; Donald B Kohn Journal: J Clin Invest Date: 2013-07-01 Impact factor: 14.808